Five Prime Therapeutics
Market Cap
US$1.0b
Last Updated
2021/02/28 23:45 UTC
Data Sources
Company Financials +
Executive Summary
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Five Prime Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FPRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: FPRX's weekly volatility has decreased from 37% to 12% over the past year.
Market Performance
7 Day Return
-6.7%
FPRX
-4.9%
US Biotechs
-3.6%
US Market
1 Year Return
480.4%
FPRX
33.7%
US Biotechs
36.5%
US Market
Return vs Industry: FPRX exceeded the US Biotechs industry which returned 33.8% over the past year.
Return vs Market: FPRX exceeded the US Market which returned 36.4% over the past year.
Shareholder returns
| FPRX | Industry | Market | |
|---|---|---|---|
| 7 Day | -6.7% | -4.9% | -3.6% |
| 30 Day | 33.0% | -2.4% | 2.7% |
| 90 Day | 18.2% | 5.1% | 7.5% |
| 1 Year | 480.4%480.4% | 35.7%33.7% | 39.5%36.5% |
| 3 Year | 12.3%12.3% | 19.4%13.3% | 53.5%43.6% |
| 5 Year | -35.6%-35.6% | 52.1%41.0% | 117.5%93.2% |
Long-Term Price Volatility Vs. Market
How volatile is Five Prime Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Is Five Prime Therapeutics' (NASDAQ:FPRX) Share Price Gain Of 198% Well Earned?2 months ago | Simply Wall St
Is Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Trading At A 43% Discount?3 months ago | Simply Wall St
Is Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Popular Amongst Institutions?Valuation
Is Five Prime Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FPRX ($22.23) is trading below our estimate of fair value ($110.21)
Significantly Below Fair Value: FPRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FPRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: FPRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FPRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FPRX is overvalued based on its PB Ratio (8.3x) compared to the US Biotechs industry average (4.2x).
Next Steps
Future Growth
How is Five Prime Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
32.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FPRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FPRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FPRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FPRX's revenue (53% per year) is forecast to grow faster than the US market (10.4% per year).
High Growth Revenue: FPRX's revenue (53% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FPRX is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Five Prime Therapeutics performed over the past 5 years?
-43.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FPRX is currently unprofitable.
Growing Profit Margin: FPRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FPRX is unprofitable, and losses have increased over the past 5 years at a rate of 43.9% per year.
Accelerating Growth: Unable to compare FPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FPRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.9%).
Return on Equity
High ROE: FPRX has a negative Return on Equity (-99.58%), as it is currently unprofitable.
Next Steps
Financial Health
How is Five Prime Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: FPRX's short term assets ($123.3M) exceed its short term liabilities ($23.0M).
Long Term Liabilities: FPRX's short term assets ($123.3M) exceed its long term liabilities ($42.1M).
Debt to Equity History and Analysis
Debt Level: FPRX is debt free.
Reducing Debt: FPRX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FPRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FPRX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 37.1% each year.
Next Steps
Dividend
What is Five Prime Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FPRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FPRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FPRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.6yrs
Average management tenure
CEO
Tom Civik (51 yo)
0.83
Tenure
Mr. Thomas Civik, also known as Tom, serves as President and Chief Executive Officer and Director at Five Prime Therapeutics, Inc. since April 13, 2020. Mr. Civik served as a Chief Commercial Officer of Fo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP & Chief Medical Officer | 3.92yrs | US$1.60m | 0.17% $ 1.8m | |
| Chief Strategy Officer & Secretary | 10.17yrs | US$1.51m | 0.28% $ 2.8m | |
| President | 0.83yr | no data | 0.17% $ 1.7m | |
| Executive VP & CFO | 2.25yrs | US$2.43m | 0.16% $ 1.6m | |
| Principal Accounting Officer | 2yrs | no data | 0.077% $ 775.4k | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior Vice President of Strategic Technology Operations | 3yrs | no data | no data |
2.6yrs
Average Tenure
56yo
Average Age
Experienced Management: FPRX's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 0.83yr | no data | 0.17% $ 1.7m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of the Board | 2.08yrs | US$1.28m | 0.022% $ 222.3k | |
| Independent Director | 9.58yrs | US$132.11k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 10.42yrs | US$115.86k | 0.011% $ 111.2k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.75yrs | US$127.74k | 0% $ 0 | |
| Independent Director | 5.17yrs | US$113.36k | 0% $ 0 |
4.5yrs
Average Tenure
71yo
Average Age
Experienced Board: FPRX's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.3%.
Top Shareholders
Company Information
Five Prime Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Five Prime Therapeutics, Inc.
- Ticker: FPRX
- Exchange: NasdaqGS
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.008b
- Shares outstanding: 45.35m
- Website: https://www.fiveprime.com
Number of Employees
Location
- Five Prime Therapeutics, Inc.
- 111 Oyster Point Boulevard
- South San Francisco
- California
- 94080
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FPRX | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Sep 2013 |
| 5P8 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Sep 2013 |
Biography
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company’s product candidates comprise Bemarituzumab, ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/02/28 23:45 |
| End of Day Share Price | 2021/02/26 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.